LITS Is the First and Solely US Publicly Traded Firm to Achieve Institutional Publicity to LTC, Holding 929,548 LTC Tokens.
Lite Technique, Inc. (NASDAQ: LITS) (“Lite Technique” or “LITS”) as we speak reported outcomes for its first quarter ended September 30, 2025, and highlighted latest company occasions associated to the Firm’s digital asset treasury technique in addition to its pharmaceutical operations.
“Our first quarter was extremely profitable for LITS. We launched our digital treasury technique, positioning ourselves because the main public holder of LTC, and up to date our company profile to bolster our new focus,” Board Member Charlie Lee mentioned. “We not too long ago celebrated Litecoin’s 14th anniversary and its unblemished monitor report of reliability and uptime. LITS gives buyers the one US publicly traded firm to realize institutional publicity to Litecoin, each for portfolio diversification and long-term worth.”
“Fiscal yr 2026 will showcase the outcomes of the transformative steps taken by Lite Technique. For the reason that begin of our strategic alternate options course of in fiscal yr 2025, we now have prioritized maximizing the worth of our property for stockholders. Beginning with the profitable sale of our medical asset, ME-344 (now often called WE-868), presently being developed for adults with weight problems at Aardvark Therapeutics, and persevering with via the shut of our $100 million PIPE providing in July 2025 that kicked off our Litecoin digital asset treasury technique within the first quarter of this fiscal yr,” mentioned Jay File, CEO, CFO.
First Quarter Fiscal Yr 2026 and Current Highlights
- Raised $100 million in mixture gross proceeds, commencing the Firm’s long-term strategic plan with Litecoin as a digital asset treasury reserve asset.
- Formally turned the primary U.S.-listed public firm to undertake Litecoin as a main reserve asset with the acquisition of 929,548 Litecoin (LTC) tokens, implementing a brand new technique constructed on a digital asset infrastructure and long-term capital innovation.
- Entered right into a strategic partnership with GSR, a number one crypto funding agency, to information LITS’ digital asset treasury technique, making certain sturdy governance, execution, and market experience.
- Introduced on world-class board members, Charlie Lee, creator of Litecoin, and Joshua Riezman, U.S. Chief Technique Officer at GSR.
- Rebranded from MEI Pharma to Lite Technique, together with altering the Firm’s company title and NASDAQ Inventory Market ticker from MEIP to LITS, and unveiling a brand new company brand and web site. The rebranding underscores the Firm’s dedication to constructing a long-term company technique round LTC as its main reserve asset.
- In October introduced a $25 million share repurchase program, advancing LITS from the preliminary section of Litecoin accumulation to lively capital market operations and permitting LITS to leverage our practically 1 million LTC treasury – a key differential from passive funding buildings like exchange-traded funds.
“As we progress additional into fiscal yr 2026, we proceed to judge our medical property together with the graduation of pre-clinical research with voruciclib in non-oncology illness indications for potential licensing to 3rd events, and pursuing licensing or sale alternatives with zandelisib,” mentioned Jay File. “We are going to think about alternatives to deploy our not too long ago introduced $25 million inventory buyback program till our low cost to NAV is normalized. We look ahead to executing on all our company goals as we progress via fiscal yr 2026.”
As of September 30, 2025, the Firm had $12.21 million in working capital with no excellent debt.
To study extra about Lite Technique, go to the Firm’s homepage at https://litestrategy.com.
To study extra about Litecoin and its function in Lite Technique’s treasury, go to the About Litecoin web page at https://litestrategy.com/about-litecoin/.
To study extra concerning the transaction with Aardvark, learn the Type 8-Okay submitting at https://investor.meipharma.com/sec-filings/sec-filing/8-k/0000950170-24-117406.
For present holdings and associated Firm metrics, go to Lite Technique’s dashboard at https://litestrategy.com/dashboard/.
About Lite Technique, Inc. (LITS)
Lite Technique, Inc. (NASDAQ: LITS) is the primary U.S. publicly traded firm to undertake Litecoin as its main reserve asset. Previously MEI Pharma, the Firm has expanded its enterprise mannequin past its portfolio of drug candidates to give attention to pioneering institutional-grade digital asset treasury methods, in partnership with main innovators throughout blockchain, finance, and expertise.
Ahead-Wanting Statements
Sure data contained on this press launch that aren’t historic in nature are “forward-looking statements” throughout the that means of the “protected harbor” provisions of the Non-public Securities Litigation Reform Act of 1995 together with, with out limitation, statements concerning our future actions, potential merchandise and actions, future efficiency or outcomes. You need to be conscious that our precise outcomes may differ materially from these contained within the forward-looking statements, that are based mostly on administration’s present expectations and are topic to quite a lot of dangers and uncertainties, together with, however not restricted to, threat regarding having the ability to repurchase our shares available in the market on engaging phrases or in any respect, sustaining our present itemizing on Nasdaq, our capacity to retain and entice senior administration and different key workers, fluctuations available in the market value of LTC and any related impairment expenses that we might incur on account of a lower available in the market value of LTC beneath the worth at which LTC is carried on our stability sheet, modifications within the accounting remedy regarding our LTC holdings, our capacity to realize worthwhile operations, authorities regulation of cryptocurrencies and on-line betting, modifications in securities legal guidelines or rules, buyer acceptance of latest services together with our LTC treasury technique, our capacity to make the most of our repurchase program, the demand for our merchandise and our prospects’ financial situation, the impression of aggressive merchandise and pricing, our proprietary rights, basic financial situations and different threat components detailed in our annual report and different filings with the SEC. We don’t intend to replace any of those components or to publicly announce the outcomes of any revisions to those forward-looking statements.
Contact
CEO, CFO
Justin J. File
Lite Technique, Inc.
investor@litestrategy.com
858-369-7199
